Skip to main content
. Author manuscript; available in PMC: 2013 Mar 20.
Published in final edited form as: J Immunol. 2010 Nov 5;185(12):7663–7670. doi: 10.4049/jimmunol.1001707

FIGURE 9. MM218 is effective when administered directly to the airways.

FIGURE 9

Mice were primed/challenged with OVA, with groups of mice (n=6) given difference doses of MM218 by i.n. delivery during challenge. Data show a significant reduction in effector/memory CD4+ T cells and eosinophils in MM218 treated mice. Student’s t-test established *** P<0.001 and ** P<0.01 levels of statistical difference comparing OVA + MM218 to OVA + PBS groups. These data are representative of 2 independent experiments.